Overview
Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2022-08-01
2022-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This multi-center, open-label, parallel-controlled, single-dose Phase 1 study is being conducted to directly characterize the pharmacokinetic (PK) profiles and safety of Jaktinib following administration of a single oral dose in subjects with varying degrees of hepatic impairment compared to healthy matched control subjects with normal hepatic function(matched by age, weight, and sex).Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Criteria
Inclusion Criteria:- Able to comprehend and willing to sign an informed consent form. Ability to comply
with trial and follow-up procedures.
- Age 18-79 years at the time of signing the ICF, either male or female.
- Male subjects body weight at least 50 kg, and female subjects body weight at least 45
kg. Body mass index (BMI) between 18 and 32 kg/m2 to participate.
- After physical examination, vital signs, laboratory examinations, 12-lead
electrocardiogram examination, the investigator determined that it is suitable to
participate in this study.
- Subjects are willing to take effective contraceptive measures from screening to 3
months after administration.
Additional Inclusion Criteria for Hepatic Impaired Subjects Only:
- Child-Pugh Clinical Assessment Score consistent with degree of hepatic
impairment(Requires no use of albumin within 14 days), And it is dysfunction caused by
previous primary liver disease.
- Any examination such as B-ultrasound, CT, MRI, FibroScan or liver biopsy confirms the
presence of cirrhosis.
Additional Inclusion Criteria for Healthy Subjects Only:
- Have not taken any medicine within 2 weeks before administration; or have stable
medication for at least 4 weeks before administration for the treatment of other
comorbid diseases.
Exclusion Criteria:
- Drug-induced liver injury.
- Acute liver damage caused by various reasons.
- Patients with liver failure, or combined with dominant hepatic encephalopathy, liver
cancer, etc., which the investigator believes are not suitable for participating in
the study.
- Patients with a history of massive bleeding from esophageal varices without band
ligation, sclerosing agent and TIPS treatment
- Subjects with suspected allergies to Jaktinib or its excipient.
- History of blood donation of 400 mL or more of blood within 3 months prior to
screening.
- Drug dependency, a positive urine drug screen.
- Subjects with any significant clinical and laboratory abnormalities which may affect
the safety evaluation.
- Subjects suffering from arrhythmia and requiring treatment, or QTcB > 480ms at
screening.
- Subjects with clinical symptoms of active bacterial, viral, parasitic or fungal
infections requiring treatment at screening.
- Subjects with known human immunodeficiency virus (HIV),
- Subjects with epilepsy or patients who have received psychotropic drug or sedatives
during screening.
- Subjects who had experienced malignant tumors within the past 5 years (except for
adequately treated local basal cell carcinoma of the skin and cervical carcinoma in
situ that have been cured).
- Subjects who have participated in another clinical trial of a new drug or medical
instrument within 3 months before screening.
- Females who are breastfeeding or pregnant at Screening.
Exclusion Criteria for Healthy Subjects Only:
- Subjects with hepatitis B surface antigen positive or HCV-RNA positive.
- Patients with a history of liver dysfunction, or physical examination and laboratory
examination at screening indicate that there is or may have liver dysfunction.